Advertisement

The significant value of predicting prognosis in patients with colorectal cancer using 18F-FDG PET metabolic parameters of primary tumors and hematological parameters

  • Junyan Xu
  • Yi Li
  • Silong Hu
  • Linjun Lu
  • Zhiqi Gao
  • Huiyu Yuan
Original Article
  • 18 Downloads

Abstract

Objects

The purpose was to evaluate the correlation of the pre-treatment hematological parameters with metabolic parameters of primary tumor in baseline 18F-FDG PET/CT in patients with colorectal cancer (CRC) and estimate the prognostic value of both.

Methods

We retrospectively investigated 231 patients with CRC who underwent baseline 18F-FDG PET/CT. Routine blood sampling was tested in the same term. PET parameters in term of hematological parameters and pathological characteristics of primary tumor were compared. Kaplan–Meier survival analysis was performed in the patients without distant metastasis. The differences of disease-free survival between groups were compared by log-rank tests.

Results

Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) were significantly correlated with all the metabolic parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG). The patients with NLR > 3 had higher MTV (24.82 ± 18.16 vs 19.06 ± 13.30, P = 0.039) and TLG (219.04 ± 186.94 vs 166.45 ± 146.39, P = 0.047) than those whose NLR ≤ 3. NLR in those patients with distant metastasis was significantly higher than those without distant metastasis (P = 0.018) while LMR in those patients with distant metastasis was significantly lower than those without distant metastasis (P = 0.032). Survival analysis showed that those patients with low MTV (P = 0.015), low NLR (P = 0.008) and high LMR (P = 0.027) revealed significant survival benefit.

Conclusions

There was a significant association between the pre-treatment hematological parameters and metabolic parameters of baseline 18F-FDG PET/CT in the patients with CRC. It might be helpful in those patients with high NLR and low LMR to undergo 18F-FDG PET/CT to detect distant metastasis and predict prognosis.

Keywords

Colorectal cancer PET NLR LMR Prognosis 

References

  1. 1.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefGoogle Scholar
  3. 3.
    Oliphant R, Nicholson GA, Horgan PG, Molloy RG, McMillan DC, Morrison DS, et al. Contribution of surgical specialization to improved colorectal cancer survival. Br J Surg. 2013;100(10):1388–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017;7(1):1494.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kim IH, Lee JE, Yang JH, Jeong JW, Ro S, Lee MA. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia Pac J Clin Oncol. 2018;14(3):239–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhan X, Sun X, Hong Y, Wang Y, Ding K. Combined detection of preoperative neutrophil-to-lymphocyte ratio and CEA as an independent prognostic factor in nonmetastatic patients undergoing colorectal cancer resection is superior to NLR or CEA alone. Biomed Res Int. 2017;2017:3809464.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wu Y, Li C, Zhao J, Yang L, Liu F, Zheng H, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol. 2016;14(1):289.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li H, Song J, Cao M, Wang G, Li L, Zhang B, et al. Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer. Int Immunopharmacol. 2016;40:327–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol. 2017;23(3):505–15.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017;265(3):539–46.CrossRefPubMedGoogle Scholar
  11. 11.
    Song Y, Yang Y, Gao P, Chen X, Yu D, Xu Y, et al. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer. BMC Cancer. 2017;17(1):744.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31(12):305.CrossRefPubMedGoogle Scholar
  13. 13.
    Azab B, Mohammad F, Shah N, Vonfrolio S, Lu W, Kedia S, et al. The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer. Cancer Biomark. 2014;14(5):303–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Laurens ST, Oyen WJ. Impact of fluorodeoxyglucose PET/computed tomography on the management of patients with colorectal cancer. PET Clin. 2015;10(3):345–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee JY, Yoon SM, Kim JT, Kim KB, Kim MJ, Park JG, et al. Diagnostic and prognostic value of preoperative (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography. Intest Res. 2017;15(2):208–14.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shi D, Cai G, Peng J, Li D, Li X, Xu Y, et al. The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer. BMC Cancer. 2015;15:991.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jo HJ, Kim SJ, Lee HY, Kim IJ. Prediction of survival and cancer recurrence using metabolic volumetric parameters measured by 18F-FDG PET/CT in patients with surgically resected rectal cancer. Clin Nucl Med. 2014;39(6):493–7.PubMedGoogle Scholar
  18. 18.
    Lee HS, Kim HO, Hong YS, Kim TW, Kim JC, Yu CS, et al. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med. 2014;55(4):582–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Lim Y, Bang JI, Han SW, Paeng JC, Lee KH, Kim JH, et al. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging. 2017;44(5):757–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Surucu E, Demir Y, Sengoz T. The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. Ann Nucl Med. 2015;29(10):906–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefPubMedGoogle Scholar
  22. 22.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  23. 23.
    Jeong E, Hyun SH, Moon SH, Cho YS, Kim BT, Lee KH. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection. Medicine (Baltimore). 2017;96(5):e5935.CrossRefGoogle Scholar
  24. 24.
    Ozyurek BA, Ozmen O, Ozdemirel TS, Erdogan Y, Kaplan B, Kaplan T. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma. Clin Respir J. 2018;12(2):646–51.CrossRefPubMedGoogle Scholar
  25. 25.
    McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16(8):717–27.CrossRefPubMedGoogle Scholar
  26. 26.
    McSorley ST, Khor BY, Tsang K, Colville D, Han S, Horgan PG, et al. The relationship between (18) F-FDG-PETCT-derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer. Colorectal Dis. 2018;20(5):407–15.CrossRefPubMedGoogle Scholar
  27. 27.
    Xiao WW, Zhang LN, You KY, Huang R, Yu X, Ding PR, et al. A low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in pathological T3N0 rectal cancer patients following total mesorectal excision. J Cancer. 2015;6(7):616–22.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Ozawa T, Ishihara S, Kawai K, Kazama S, Yamaguchi H, Sunami E, et al. Impact of a lymphocyte to monocyte ratio in stage IV colorectal cancer. J Surg Res. 2015;199(2):386–92.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  • Junyan Xu
    • 1
    • 2
    • 3
    • 4
    • 5
  • Yi Li
    • 1
    • 2
    • 3
    • 4
    • 5
  • Silong Hu
    • 1
    • 2
    • 3
    • 4
    • 5
  • Linjun Lu
    • 1
    • 2
    • 3
    • 4
    • 5
  • Zhiqi Gao
    • 1
    • 2
    • 3
    • 4
    • 5
  • Huiyu Yuan
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Department of Nuclear MedicineFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Center for Biomedical ImagingFudan UniversityShanghaiChina
  3. 3.Shanghai Engineering Research Center of Molecular Imaging ProbesFudan UniversityShanghaiChina
  4. 4.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  5. 5.Key Laboratory of Nuclear Physics and Ion-beam Application (MOE)Fudan UniversityShanghaiChina

Personalised recommendations